Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) experienced a dramatic surge of approximately 252% during late morning trading on Tuesday, June 30, 2026. The sharp rally followed the company's decision to withdraw a previously filed S-1 registration statement, which had raised concerns among investors about potential dilution. The stock, which closed at around $0.81 on Monday, rocketed to an intraday high of $4.62 before settling near $2.85, representing a gain of over $2.04 per share.
The withdrawn S-1 filing, originally submitted on June 25, had proposed the sale of up to 3.05 million common shares along with warrants for an additional 6.09 million shares. The offering also included existing warrants covering roughly 6.10 million shares, creating a potential dilution scenario that had weighed on the stock. In a Rule 477 withdrawal notice filed with the Securities and Exchange Commission (SEC), Creative Medical stated that it no longer plans to consummate the offering and confirmed that no securities were sold under the withdrawn statement.
Trading volume exploded to 146.1 million shares, nearly 40 times the 3.70 million shares outstanding listed in the withdrawn filing. This massive turnover underscores the intense market interest and speculative activity surrounding the biotech stock. The rally was particularly notable given that the broader biotech sector remained relatively flat, with the SPDR S&P Biotech ETF (NYSEARCA:XBI) and iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) both gaining only about 0.5% on the day.
The withdrawal effectively removes the immediate overhang of potential dilution, but the company's financial runway remains a key consideration. According to the S-1/A filing, Creative Medical held $5.72 million in cash as of March 31, 2026. The proposed offering had aimed to raise approximately $5.34 million in net proceeds, which would have extended the company's ability to fund operations into December 2027. However, the filing also acknowledged that even with those proceeds, the company would still fall short of taking any products through regulatory approval.
The rally has also shifted the dynamics of existing warrants. The S-1/A detailed that warrants issued in October 2025 cover up to 2.79 million shares at an exercise price of $2.86 each, exercisable for five years following shareholder approval on December 26, 2025. At the current trading price of $2.85, CELZ is just below that strike level, but earlier in the session, the stock traded above it, making the warrants potentially in-the-money.
On the clinical front, Creative Medical announced on June 22 that it received FDA clearance to expand its ADAPT study of CELZ-201 (Olastrocel) for chronic low back pain associated with degenerative disc disease. The expansion adds a 15-patient cohort using less than 90 mg per day of morphine equivalents, with more than 85% of the group already enrolled. An independent safety board gave the cohort a clean review, reporting no major adverse events. CEO Timothy Warbington described the FDA green light as "another important step" for the company.
Market participants are now weighing the implications of the withdrawn offering against the company's cash position and clinical progress. While the stock has received a significant short-term boost, the fundamental challenges remain: Creative Medical still needs substantial capital to advance its pipeline through regulatory milestones. The company has requested that the SEC apply its filing fees to future registrations, but no new financing arrangements have been announced.
The dramatic price action and volume surge suggest that the stock may continue to experience elevated volatility in the near term. Investors will be closely watching for any updates on financing plans or clinical developments that could further influence the stock's trajectory. The biotech sector, while broadly stable, has shown that company-specific catalysts can drive outsized moves, particularly for small-cap names like CELZ.
